Navigation Links
Saladax Biomedical Enters into Master Collaboration Agreement with Bristol-Myers Squibb
Date:8/6/2012

BETHLEHEM, Pa., Aug. 6, 2012 /PRNewswire/ -- Saladax Biomedical, Inc., a privately held company developing and commercializing novel diagnostic assays to achieve the promise of personalized medicine for new and existing therapeutics, announced today the company has expanded its existing relationship with Bristol-Myers Squibb Company (NYSE: BMY) by entering into a Master Early Development Collaboration Agreement, which may include multiple feasibility studies and companion diagnostic development projects.  With the signing of this agreement, the companies have already initiated a new companion diagnostic project in an undisclosed field.  Terms of the agreement were not disclosed.

"Saladax is delighted to continue working with Bristol-Myers Squibb to deliver on the promise of personalized medicine," said Kevin M. Harter, president and CEO of Saladax.  "Building on our previous work together, which resulted in clinically valuable Alzheimer's disease assays, we're eager to continue marrying the scientific and clinical knowledge of Bristol-Myers Squibb and Saladax to improve the lives of patients in other clinical areas."

Saladax and Bristol-Myers Squibb originally entered into a collaboration in 2010 for the development of clinical diagnostic tests for Alzheimer's disease to be used in conjunction with the development of certain therapeutic compounds in the Bristol-Myers Squibb pipeline.  In 2011, that partnership was expanded to include a commercial partner, Johnson & Johnson's Ortho Clinical Division.

About Saladax Biomedical, Inc.

Saladax Biomedical develops novel diagnostic assays for the practical delivery of personalized medicine. Our proprietary line of MyCare™ assays improves the efficacy of existing drugs by optimizing the dose administered for each individual patient. Saladax's initial focus is oncology, with a portfolio of 13 chemotherapy drug assays in various stages of development.  Three MyCare assays, My5- FU™, MyPaclitaxel™ and MyDocetaxel™, are currently offered to the oncology community in some markets.

The company's MyCare technology platform is broad and flexible, enabling wide application in many therapeutic categories. This technology capability also enables Saladax to serve as a valuable partner to pharmaceutical and biotechnology companies in the development of companion diagnostics (CDx), addressing multiple risks and challenges encountered in drug development.

The company was founded in 2004 and is headquartered in Bethlehem, Pennsylvania. Saladax is ISO 13485:2003 certified.

Saladax Biomedical, Inc.

Kevin M. Harter

President and Chief Executive Officer

kharter@saladax.com

Media Contact:

Tiberend Strategic Advisors, Inc.

212-827-0020

Andrew Mielach or Claire Sojda

amielach@tiberend.com

csojda@tiberend.com


'/>"/>
SOURCE Saladax Biomedical, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Related biology news :

1. Nuisance seaweed found to produce compounds with biomedical potential
2. MADRID-MIT M+Vision Consortium hosts Biomedical Innovation Conference 2012
3. UMass Medical School scientist named 2012 Pew Latin-American Fellow in the Biomedical Sciences
4. 22 of Americas most promising scientists selected as Pew Biomedical Scholars
5. Top young Latin-American scientists named Pew Biomedical Fellows
6. Master molecule may improve stem cell treatment of heart attacks
7. Novo Nordisk and BGI establish global collaboration framework
8. Copernicus Award 2012 for German-Polish collaboration in business information systems
9. Scripps Research Institute announces five-year research collaboration with Bristol-Myers Squibb
10. Grant program to spur new research on Alzheimers disease by encouraging collaboration
11. Building global collaboration for biodiversity intelligence
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/2/2017)... March 2, 2017 Summary This ... understand Merck KGaA and its partnering interests and activities ... Description The Partnering Deals and Alliance since ... activity of one of the world,s leading life sciences ... upon purchase to ensure inclusion of the most up ...
(Date:2/28/2017)... DORTMUND, Germany , February 28, 2017 ... ... Amsterdam from 14 to 16 March, ... to destination, and show how seamless travel is a real benefit ... Materna has added biometrics to their passenger touch point solutions to ...
(Date:2/22/2017)... -- With the biometrics market to exceed $10 ... that innovative and agile startups must incorporate into ... changing competitive landscape: multifactor authentication (MFA), point-of-sale (PoS), ... "Companies can no longer afford to cut corners ... Pavlakis , Industry Analyst at ABI Research. "Pairing ...
Breaking Biology News(10 mins):
(Date:3/24/2017)... 2017 Research and Markets has announced the ... Global Strategic Business Report" report to their offering. ... This report analyzes the ... Million. Annual estimates and forecasts are provided for the period 2014 ... secondary research. The report profiles 25 companies including ...
(Date:3/24/2017)... 24, 2017 Agenus Inc. (NASDAQ: AGEN), an ... and cancer vaccines, today announced participation at the following ... William Blair and Maidstone Life Sciences conference "Cancer Immunotherapy ... New York, NY . Agenus will ... at 9:40 am: Robert B. Stein , M.D., ...
(Date:3/23/2017)... , March 23, 2017  Northwest Biotherapeutics ... DCVax® personalized immune therapies for solid tumor cancers, ... $7.5 million financing it announced last Friday, March ... to several institutional investors securities totaling 28,843,692 shares, ... share, and 10,000,000 shares of Class C Warrants ...
(Date:3/23/2017)... ... March 23, 2017 , ... Ellen ... the Connecticut Technology Council (CTC) as a 2017 Women of Innovation® finalist. Matloff ... of Innovation Awards Dinner. , The dinner recognizes women accomplished in science, technology, ...
Breaking Biology Technology: